SSY Group (HKSE:02005) Debt-to-Revenue : 0.54 (As of Dec. 2023)

View and export this data going back to 2005. Start your Free Trial

What is SSY Group Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

SSY Group's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$1,423 Mil. SSY Group's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$1,951 Mil. SSY Group's annualized Revenue for the quarter that ended in Dec. 2023 was HK$6,260 Mil. SSY Group's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 was 0.54.

SSY Group Debt-to-Revenue Historical Data

The historical data trend for SSY Group's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SSY Group Debt-to-Revenue Chart

SSY Group Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Revenue

Get a 7-Day Free Trial

0.37

0.57

0.58

0.50

0.52

SSY Group Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Revenue	Get a 7-Day Free Trial															0.53	0.49	0.53	0.51	0.54

Competitive Comparison of SSY Group's Debt-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, SSY Group's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SSY Group's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, SSY Group's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where SSY Group's Debt-to-Revenue falls into.

SSY Group Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

SSY Group's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(1422.761	+	1951.327)	/	6463.009
	=	0.52

SSY Group's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(1422.761	+	1951.327)	/	6259.704
	=	0.54

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is two times the quarterly (Dec. 2023) Revenue data.

SSY Group Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of SSY Group's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

SSY Group (HKSE:02005) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » SSY Group Ltd (HKSE:02005) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

Central Plaza, 18 Harbour Road, Rooms 4902-03, 49th Floor, Wanchai, Hong Kong, HKG

Website

http://www.ssygroup.com.hk

SSY Group Ltd is engaged in the research, development, manufacturing and selling of a wide range of pharmaceutical products, which includes finished medicines of mainly intravenous infusion solution and ampoule injection to hospitals and distributors, bulk pharmaceuticals and medical materials. The company has two reportable segments including intravenous infusion solution and others and medical materials. The company derives a vast majority of its revenue principally from the Intravenous infusion solution and others. Revenue generation is driven mostly by its sales of pharmaceutical products, followed by medical materials.

SSY Group (HKSE:02005) Headlines

No Headlines